Lenvatinib plus pembrolizumab increased survival for advanced endometrial cancer patients when compared to chemotherapy

1. The median progression-free survival and overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy. 2. Clinically important adverse events in the combination group included hypertension, thyroid dysfunction, colitis and diarrhea Evidence Rating Level: 1 (Excellent) Study Rundown: Advanced endometrial cancer after platinum treatment remains difficult to treat and fiver-year survival remains poor. […]